Brief: Sellas Life Sciences Enters Agreement With Impact-Aml To Expand SLS009 Clinical Program Into Europe
14/01/2026 13:37
Jan 14 (Reuters) - Sellas Life Sciences Group Inc SLS.O: SELLAS LIFE SCIENCES ENTERS AGREEMENT WITH IMPACT-AML TO EXPAND SLS009 CLINICAL PROGRAM INTO EUROPE SELLAS LIFE SCIENCES GROUP INC - SLS009 U.S. ENROLLMENT PLANNED FOR Q1 2026, EUROPE ENROLLMENT ANTICIPATED IN Q2 2026 Source text: ID:nGNXbTG4n3 Further company coverage: SLS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses